TNF and venous thromboembolism: Although Janus kinase inhibitors have an oral route of administration, they must be used after failure of ≥1 anti-tumor necrosis factor agent in the United States and may be associated with serious side effects, including increased risk of major adverse cardiovascular events, venous thromboembolism, and malignancy.33